MISTIE III: A Phase III, Randomized, Open-Label, 500-Subject Clinical Trial of Minimally Invasive Surgery Plus rt-PA in the Treatment of Intracerebral Hemorrhage

Trial ID or NCT#

NCT01827046

Status

not recruiting iconNOT RECRUITING

Purpose

The study will evaluate the efficacy and safety of minimally invasive surgery plus 1 mg of rt-PA administered every eight hours for up to nine doses as compared to subjects treated with conventional medical management.

 

 

Investigator(s)

Chitra Venkatasubramanian, MBBS, MD

View on ClinicalTrials.gov